Revolution Medicines, Inc. (RVMD)
210.02
-0.85
(-0.40%)
USD |
NASDAQ |
Sep 04, 16:00
209.26
-0.76
(-0.36%)
After-Hours: 20:00
Revolution Medicines Research and Development Expense (Quarterly) : 392.47M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 392.47M |
| March 31, 2026 | 341.62M |
| December 31, 2025 | 292.61M |
| September 30, 2025 | 260.18M |
| June 30, 2025 | 222.11M |
| March 31, 2025 | 203.79M |
| December 31, 2024 | 186.09M |
| September 30, 2024 | 149.85M |
| June 30, 2024 | 133.02M |
| March 31, 2024 | 116.21M |
| December 31, 2023 | 146.87M |
| September 30, 2023 | 106.20M |
| June 30, 2023 | 96.49M |
| March 31, 2023 | 67.48M |
| December 31, 2022 | 64.71M |
| September 30, 2022 | 68.20M |
| Date | Value |
|---|---|
| June 30, 2022 | 59.80M |
| March 31, 2022 | 55.32M |
| December 31, 2021 | 52.60M |
| September 30, 2021 | 45.41M |
| June 30, 2021 | 44.86M |
| March 31, 2021 | 39.92M |
| December 31, 2020 | 36.06M |
| September 30, 2020 | 33.94M |
| June 30, 2020 | 32.01M |
| March 31, 2020 | 26.56M |
| December 31, 2019 | 27.49M |
| September 30, 2019 | 22.09M |
| June 30, 2019 | 19.31M |
| March 31, 2019 | 20.39M |
| December 31, 2018 | 18.18M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Tango Therapeutics, Inc. | 36.77M |
| Erasca, Inc. | 35.90M |
| Moderna, Inc. | 588.00M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Intellia Therapeutics, Inc. | 80.50M |